AlphaRx Files Patent Application For Oral Drug Delivery System.Business Editors, Health/Medical Writers BIOWIRE2K RICHMOND, Ontario--(BW HealthWire)--Dec. 13, 2000 AlphaRx Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AHRX) today announced that it has filed a patent application with the U.S. Patent Office to broaden the claims and protection on its drug delivery systems. The delivery technology covered in this patent application has widespread application for enhanced, targeted delivery of hydrophobic hydrophobic /hy·dro·pho·bic/ (-fo´bik) 1. pertaining to hydrophobia (rabies). 2. not readily absorbing water, or being adversely affected by water. 3. natural compounds. Self-emulsifying drug delivery systems (SEDDS SEDDS Self-Emulsifying Drug Delivery System ) are good candidates for the oral delivery of hydrophobic drugs because of their ability to form fine oil-in-water (o/w) emulsions or microemulsions upon mild agitation following dilution in aqueous phase aqueous phase n. The water portion of a system consisting of two liquid phases, one that is primarily water and a second that is a liquid immiscible with water. . The extensive research in self-emulsifying drug delivery systems (SEDDS) has led to the design of other lipid self-dispersing vehicles capable of forming drug-loaded fine lipid particles in the gastrointestinal (GI) lumen. These self-microemulsifying or microencapsulated microencapsulated Therapeutics adjective Surrounded by a thin layer of biodegradable substance–eg, a microsphere, as a means of protecting a drug or vaccine antigen from rapid breakdown, or of enhancing antigenic absorption and immune response thereto formulations have been proposed as alternatives to conventional SEDDS. All of these formulations produce fine oil droplet/micelle dispersions upon aqueous dilution but can only be administrated in soft or hard gelatin gelatin or animal jelly, foodstuff obtained from connective tissue (found in hoofs, bones, tendons, ligaments, and cartilage) of vertebrate animals by the action of boiling water or dilute acid. capsules. This presents a serious technological and manufacturing limitation. AlphaRx's Self-emulsifying Control Released Tablet (SECRET) system has distinct advantages over these SEDDS. They include:
1. The ability to modulate drug release with a reproducible
release rate.
2. The ability to protect drugs against decomposition in the GI
tract.
3. Compatibility with conventional tablet manufacturing and
packaging.
4. They are not pH dependent.
5. Reduced food effect.
6. Once-a-day dosage capability.
7. Application to a wide range of compounds.
8. The possibility of delivering protein and peptide through oral
formulations.
"AlphaRx's SECRET system is versatile and offers significant flexibility in the development of suitable dosage formulations (i.e. Immediate Release or Controlled Release) to meet the requirements of specific molecules." Said Mr. Michael Lee, President of AlphaRx. "With more than 40% of new chemical entities exhibiting poor aqueous solubility and complex technical formulation problems, the SECRET system will have an increasing application in the delivery of lipophilic lipophilic, adj/n the ability to dissolve or attach to lipids. lipophilic (lipōfil´ik), adj 1. showing a marked attraction to, or solubility in, lipids. 2. drugs." The Company now has one issued U.S. patent and four U.S. patent applications relating to its BCD (Binary Coded Decimal) The storage of numbers in which each decimal digit is converted into binary and is stored in a single character or byte. For example, a 12-digit number would take 12 bytes. See binary numbers. drug delivery systems. Corresponding international patent applications are pending. About AlphaRx AlphaRx is engaged in the development of novel formulations of drugs that are insoluble or poorly soluble in water. AlphaRx's broad product pipeline consists of carefully selected, mainly currently marketed drugs which, through the application of its proprietary BCD drug delivery systems, offer improved medical benefits over existing products as well as strong commercial potential. For additional information, please visit our web-site at www.AlphaRx.com FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion